IRVINE, Calif., Nov. 16, 2020 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating its second annual BOTOX® Cosmetic Day on Wednesday, November 18, 2020. The event is dedicated to celebrating the iconic treatment that helped create the aesthetics industry and recognizing the loyal community of patients and healthcare providers who have helped make this brand what it is today. In addition, this is a day for both new and loyal BOTOX® Cosmetic users to put themselves first with an exclusive one-day-only offer available while supplies last exclusively through AllēSM, the new loyalty platform from Allergan Aesthetics.
NORTH CHICAGO, Ill., Nov. 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Thursday, November 19, 2020. Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive vice president and chief financial officer, will present at 11:35 a.m. Central time.
NORTH CHICAGO, Ill., Nov. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it will present blood cancer data from nearly 40 abstracts, including 10 oral presentations, across 11 cancer types during the upcoming virtual American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8.
NORTH CHICAGO, Ill., Oct. 30, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2020.
NORTH CHICAGO, Ill., Oct. 29, 2020 /PRNewswire/ -- Late-breaking data analyses to be presented by AbbVie (NYSE: ABBV) at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadacitinib (15 mg or 30 mg; once daily) monotherapy achieved improvement in additional measures of skin clearance and reduction in itch compared to placebo.1 These data are from the Phase 3 Measure Up 1 and Measure Up 2 studies, which support the recent applications to the U.S. Food and Drug Administration and European Medicines Agency, seeking approval for RINVOQ in adult and adolescent patients with moderate to severe atopic dermatitis.
NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ™ (upadacitinib) and HUMIRA® (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2020), to be held virtually November 5-9. A total of 38 abstracts, including seven oral presentations, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint. Additional details of these studies will be presented at future medical meetings and will serve as the basis for the New Drug Application submission to U.S. Food and Drug Administration (FDA) in the first half of 2021.
NORTH CHICAGO, Ill., Oct. 19, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ™ (upadacitinib) for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate to severe atopic dermatitis.
Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.
Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.
Receive alerts on new stories, articles, and more by subscribing to one or more RSS Feeds.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?
